Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Fortress Biotech, Inc.v427296_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

  

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 30, 2015

 

 

FORTRESS BIOTECH, INC.
(Exact Name of Registrant as Specified in Charter)

 

 

Delaware 001-35366 20-5157386

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

3 Columbus Circle, 15th Floor, New York, New York 10019
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 652-4500

 

 
(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  (17 CFR 240.13e-4(c))

  

 

 

 

Item 8.01. Other Events

 

On December 30, 2015, Fortress Biotech, Inc.’s subsidiary, Avenue Therapeutics, Inc., issued a press release announcing that it filed a registration statement on Form 10 with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, for the purpose of becoming a reporting company. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d)Exhibits

 

  Exhibit No. Description
       
  99.1     Avenue Therapeutics press release dated December 30, 2015.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  FORTRESS BIOTECH, INC.
     
     
Date:  December 30, 2015 /s/  Lindsay A. Rosenwald
  Name:   Lindsay A. Rosenwald
  Title: Chairman, President and Chief Executive Officer